ANAPTYSBIO, INC. Unrealized Gain (Loss) on Investments
ANAPTYSBIO, INC. (ANAB) reported Unrealized Gain (Loss) on Investments of -$30.00 thousand for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2026-09-21
- ANAPTYSBIO, INC. unrealized gain (loss) on investments for the quarter ending 2026-06-30 was -$38.00K, a 102.38% decline year-over-year.
- ANAPTYSBIO, INC. unrealized gain (loss) on investments for the quarter ending 2026-03-31 was $8.00K, a 99.52% decline year-over-year.
- ANAPTYSBIO, INC. unrealized gain (loss) on investments for the quarter ending 2025-12-31 was $340.00K, a 85.23% decline year-over-year.
- ANAPTYSBIO, INC. unrealized gain (loss) on investments for the quarter ending 2025-09-30 was $1.13M, a 55.96% decline year-over-year.
- ANAPTYSBIO, INC. unrealized gain (loss) on investments for fiscal 2025 was $4.73M, a 54.10% decline from fiscal 2024.
- ANAPTYSBIO, INC. unrealized gain (loss) on investments for fiscal 2024 was $10.31M, a 1.98% decline from fiscal 2023.
- ANAPTYSBIO, INC. unrealized gain (loss) on investments for fiscal 2023 was $10.52M, a 319.66% increase from fiscal 2022.
- ANAPTYSBIO, INC. unrealized gain (loss) on investments for fiscal 2022 was $2.51M.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$38.00K derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | -$30.00K 10-KT · filed 2026-09-21 | $310.00K derived: sum of 3 quarters · filed 2026-09-21 | $1.44M derived: sum of 4 quarters · filed 2026-09-21 |
| 2026-03-31 | $8.00K 10-Q · filed 2026-05-12 | $348.00K derived: sum of 2 quarters · filed 2026-09-21 | $1.48M derived: sum of 3 quarters · filed 2026-09-21 | $3.08M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-12-31 | $340.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $1.47M derived: sum of 2 quarters · filed 2026-09-21 | $3.07M derived: sum of 3 quarters · filed 2026-09-21 | $4.73M 10-KT · filed 2026-09-21 |
| 2025-09-30 | $1.13M derived: 10-Q 9 month − 10-KT 6 month · filed 2025-11-04 | $2.73M derived: sum of 2 quarters · filed 2026-09-21 | $4.39M 10-Q · filed 2025-11-04 | $6.70M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-06-30 | $1.60M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $3.26M 10-KT · filed 2026-09-21 | $5.57M derived: sum of 3 quarters · filed 2026-09-21 | $8.13M derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-03-31 | $1.67M 10-Q · filed 2026-05-12 | $3.97M derived: sum of 2 quarters · filed 2026-09-21 | $6.54M derived: sum of 3 quarters · filed 2026-09-21 | $9.01M derived: sum of 4 quarters · filed 2026-09-21 |
| 2024-12-31 | $2.30M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $4.87M derived: sum of 2 quarters · filed 2026-09-21 | $7.34M derived: sum of 3 quarters · filed 2026-09-21 | $10.31M 10-KT · filed 2026-09-21 |
| 2024-09-30 | $2.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $5.04M derived: sum of 2 quarters · filed 2025-11-04 | $8.01M 10-Q · filed 2025-11-04 | $11.16M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $5.45M 10-Q · filed 2025-08-06 | $8.60M derived: sum of 3 quarters · filed 2026-03-03 | $11.59M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $2.97M 10-Q · filed 2025-05-05 | $6.12M derived: sum of 2 quarters · filed 2026-03-03 | $9.12M derived: sum of 3 quarters · filed 2026-03-03 | $11.30M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $3.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $6.15M derived: sum of 2 quarters · filed 2026-03-03 | $8.33M derived: sum of 3 quarters · filed 2026-03-03 | $10.52M 10-K · filed 2026-03-03 |
| 2023-09-30 | $2.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $5.18M derived: sum of 2 quarters · filed 2024-11-05 | $7.37M 10-Q · filed 2024-11-05 | $9.09M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $2.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $4.37M 10-Q · filed 2024-08-05 | $6.10M derived: sum of 3 quarters · filed 2025-02-27 | $6.88M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $2.19M 10-Q · filed 2024-05-09 | $3.91M derived: sum of 2 quarters · filed 2025-02-27 | $4.70M derived: sum of 3 quarters · filed 2025-02-27 | $4.86M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.51M derived: sum of 2 quarters · filed 2025-02-27 | $2.67M derived: sum of 3 quarters · filed 2025-02-27 | $2.51M 10-K · filed 2025-02-27 |
| 2022-09-30 | $784.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $945.00K derived: sum of 2 quarters · filed 2022-11-08 | $784.00K 10-Q · filed 2022-11-08 | $684.00K derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-06-30 | $161.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | -$100.00K derived: sum of 3 quarters · filed 2024-03-11 | -$200.00K derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-03-31 | -$161.00K 10-Q · filed 2022-05-04 | -$261.00K derived: sum of 2 quarters · filed 2024-03-11 | -$361.00K derived: sum of 3 quarters · filed 2024-03-11 | -$487.00K derived: sum of 4 quarters · filed 2024-03-11 |
| 2021-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$200.00K derived: sum of 2 quarters · filed 2024-03-11 | -$326.00K derived: sum of 3 quarters · filed 2024-03-11 | -$493.00K 10-K · filed 2024-03-11 |
| 2021-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$226.00K derived: sum of 2 quarters · filed 2022-11-08 | -$393.00K 10-Q · filed 2022-11-08 | -$615.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$126.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$293.00K 10-Q · filed 2022-08-08 | -$515.00K derived: sum of 3 quarters · filed 2023-03-01 | -$693.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$167.00K 10-Q · filed 2022-05-04 | -$389.00K derived: sum of 2 quarters · filed 2023-03-01 | -$567.00K derived: sum of 3 quarters · filed 2023-03-01 | -$636.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$222.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$400.00K derived: sum of 2 quarters · filed 2023-03-01 | -$469.00K derived: sum of 3 quarters · filed 2023-03-01 | -$461.00K 10-K · filed 2023-03-01 |
| 2020-09-30 | -$178.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$247.00K derived: sum of 2 quarters · filed 2021-11-04 | -$239.00K 10-Q · filed 2021-11-04 | -$55.00K derived: sum of 4 quarters · filed 2022-03-07 |
| 2020-06-30 | -$69.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$61.00K 10-Q · filed 2021-08-09 | $123.00K derived: sum of 3 quarters · filed 2022-03-07 | $646.00K derived: sum of 4 quarters · filed 2022-03-07 |
| 2020-03-31 | $8.00K 10-Q · filed 2021-05-04 | $192.00K derived: sum of 2 quarters · filed 2022-03-07 | $715.00K derived: sum of 3 quarters · filed 2022-03-07 | $1.61M derived: sum of 4 quarters · filed 2022-03-07 |
| 2019-12-31 | $184.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $707.00K derived: sum of 2 quarters · filed 2022-03-07 | $1.60M derived: sum of 3 quarters · filed 2022-03-07 | $2.63M 10-K · filed 2022-03-07 |
| 2019-09-30 | $523.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $1.42M derived: sum of 2 quarters · filed 2020-11-04 | $2.45M 10-Q · filed 2020-11-04 | $3.13M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | $898.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $1.93M 10-Q · filed 2020-08-10 | $2.60M derived: sum of 3 quarters · filed 2020-08-10 | $2.90M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $1.03M 10-Q · filed 2020-05-06 | $1.71M derived: sum of 2 quarters · filed 2020-05-06 | $2.01M derived: sum of 3 quarters · filed 2020-05-06 | $2.18M derived: sum of 4 quarters · filed 2020-05-06 |
| 2018-12-31 | $678.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $978.00K derived: sum of 2 quarters · filed 2019-11-08 | $1.15M derived: sum of 3 quarters · filed 2019-11-08 | $1.23M 10-K · filed 2019-02-28 |
| 2018-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $472.00K derived: sum of 2 quarters · filed 2019-11-08 | $555.00K 10-Q · filed 2019-11-08 | $560.00K derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | $172.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $255.00K 10-Q · filed 2019-08-08 | $260.00K derived: sum of 3 quarters · filed 2019-08-08 | $244.00K derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $83.00K 10-Q · filed 2019-05-07 | $88.00K derived: sum of 2 quarters · filed 2019-05-07 | $72.00K derived: sum of 3 quarters · filed 2019-05-07 | |
| 2017-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$11.00K derived: sum of 2 quarters · filed 2019-02-28 | -$11.00K 10-K · filed 2019-02-28 | |
| 2017-09-30 | -$16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$16.00K 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |